The global market for diabetes mellitus and obesity is forecast to increase from $70.8bn in 2015 to $163.2bn by 2022, according to a new report by GBI Research.

Titled “Global Diabetes and Obesity Drugs Market to 2022 – Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment”, the report attributes this growth to a number of type 2 diabetes mellitus (T2DM) therapeutics in pipeline.

The majority of the T2DM therapeutics in the pipeline are indicated for type 1 diabetes mellitus (T1DM) and T2DM. Drugs in these segments are expected to significantly contribute to market growth, with some expected to achieve blockbuster status, opines GBI Research associate analyst Callum Dew.

Some of the drugs that have been approved and are in the pipeline include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide).

"Some of the drugs that have been approved and are in the pipeline include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide)."

Johnson & Johnson’s Invokana is expected to be a leader in the disease cluster, reach $3.23bn by 2022 and is set to be approved for T1DM, T2DM and obesity.

Rise in global incidence of obesity and its subsequent impact on T2DM incidence is a major reason behind the anticipated market growth, adds Callum Dew.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Drugs indicated for the treatment of obesity currently do not have a large market presence. Some products, however, are in the pipeline, while the majority are in early stages of development.

Existing drugs such as Januvia, Novolog and Invokana will dominate the diabetes mellitus and obesity market, but four of the forecasted top ten best-selling drugs of 2022 will be new, the report adds. Some of these products include dapagliflozin propanediol plus saxagliptin, NN-9535, and LixiLan.